The US Court of Appeals for the Fifth Circuit has rejected the claims of plaintiffs who said they were injured by brand-name and generic version of heartburn drug Reglan.
The unpublished per curiam opinion is just the latest in a series of rulings around the country in which such claims have been rejected after the U.S. Supreme Court ruled in Pliva v. Mensing that it was impossible for generic drug makers to meet both state-law duties to provide safer labels and the federal duty to have their generic drug labels exactly match brand-name drug labels.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
